Chugai Receives the MHLW Approval for the Additional Indication of Polivy (polatuzumab vedotin) to Treat Diffuse Large B-cell Lymphoma
Shots:
- The MHLW has approved Polivy for an additional indication in patients with prior untreated DLBCL
- The approval was based on the P-III (POLARIX) study evaluating Polivy (30/140mg, IV) + R-CHP vs R-CHOP in a ratio (1:1) in 879 patients which showed an improvement in PFS after a median follow-up of 28.2mos., rates of grade 3-4 AEs (57.7% vs 57.5%), serious AEs (34.0% vs 30.6%), grade 5 AEs (3.0% vs 2.3%), and AEs leading to dose reduction (9.2% vs 13.0%)
- The study is being conducted in collaboration with LYSA & LYSARC. Polivy is an anti-CD79b ADC that has been developed by Roche by using Seagens’ ADC technology & blocks the effects on normal cells as it attaches to CD79b & kills B-cells by delivering an anti-cancer agent
Ref: chugai pharmaceutical | Image: chugai
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
